Value through Innovation02 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next

Winners of the Making More Health Competition Bring Fresh Innovation to Solving Problems in Health


Boehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab


Pradaxa® awarded Prix Galien for most innovative product in Canada

- For NON-US, Non-Canada and NON-UK Healthcare Media Only

Boehringer Ingelheim race to the finish line in support of World Diabetes Day

- EX US and UK.

New RE-LY® sub-analyses demonstrate safety and efficacy of Pradaxa® (dabigatran etexilate) in patients with heart failure & those undergoing surgery

- For NON-US, NON-Canada and NON-UK Healthcare Media Only

Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition


BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients

- For media outside of the U.S.A only

Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment

- For media outside of the U.S.A. only

Boehringer Ingelheim gains approval of extended 4.5 hour time-window for Actilyse® in acute ischaemic stroke for majority of EU countries*

- For non-UK and non-US media

NICE issues Final Appraisal Determination (FAD) with unrestricted recommendation for Pradaxa® (dabigatran etexilate) for patients with non-valvular atrial fibrillation

- For NON-US, UK & Canada Media Only

Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe

- For European Health Media Only

Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors


BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events


European Respiratory Society (ERS) Awards Annual COPD Research Prize


Boehringer Ingelheim expands its Business with Biosimilars


New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis

- For NON-U.S Health Media Only

Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives approval in the EU

- For non-US healthcare media

Boehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPD

- For Media outside the U.S. and Canada
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next